Efficacy and Safety of E/C/F/TAF (Genvoya®) in HIV-1/Hepatitis B Co-infected Adults

Key Inclusion Criteria: * Both Cohorts 1 and 2: * The ability to understand and sign a written informed consent form, which must be obtained prior to initiation of study procedures * HIV/HBV co-infected adult males and non-pregnant and non-lactating females * No evidence of hepatocellular carcinoma (HCC) or clinical or imaging evidence of cirrhosis (ascites, variceal bleeding, encephalopathy). \--- Subjects should have documentation of an abdominal ultrasound in the 12 months prior to screening, or an abdominal ultrasound at screening, demonstrating the absence of cirrhosis and HCC. * Acute Hepatitis A virus (HAV) immunoglobulin M (IgM) negative * Hepatitis C virus (HCV) Ab negative, or HCV Ab positive with negative HCV RNA * Hepatitis D virus (HDV) Ab negative, or HDV Ab positive with negative HDV RNA * Estimated glomerular filtration rate (eGFR) ≥ 50 mL/min according to the Cockcroft-Gault formula * CD4+ count of \> 200 cells/μL * Chronic HBV infection as defined by * HBsAg positive for ≥ 6 months Or * HBsAg positive at screening and either hepatitis B e antigen (HBeAg) or HBV DNA positive ≥ 6 months Or * At screening: positive total hepatitis B core antibody (HBcAb) and negative immunoglobulin M antibody to hepatitis B core antigen (HBcIgM) antibody, and * HBsAg positive, or * HBeAg positive, or * HBV DNA positive * Cohort 1 (HIV and HBV treatment naive) only: * No current or prior anti-HIV treatment, including an…